Novamind to Assess Opportunities in the Psychedelic Industry

TORONTO, Ontario – May 22, 2019 – Novamind Ventures Inc. (”Novamind”) is pleased to announce that it has incorporated pursuant to the Ontario Business Corporations Act with its registered and head office located at 10 Wanless Ave, Suite 201, Toronto, ON, Canada.

Novamind was formed to pursue a pipeline of early-stage investments in world-leading clinics, retreats and technologies that enable psychedelic treatments and experiences.

Novamind is focused on addressing the world’s mental health crisis through the integration of psychedelic-assisted psychotherapy into modern psychiatry. Early data collected from current U.S Food and Drug Administration clinical trials suggest that psychedelics will revolutionize the treatment of mental health disorders including: anxiety, depression, post-traumatic stress disorder and addiction.

The need for innovative mental healthcare has never been higher. According to the World Health Organization, mental health disorders will affect one in four people worldwide during their lifetime. Mental health disorders are considered among the leading causes of sickness and disability and it is estimated that 450 million people are currently suffering from such disorders.

Throughout 2019, Novamind will announce its first investments that aim to advance psychedelic research and catalyze personal wellness.

About Novamind

Novamind invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats.  We seek to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. Novamind is building a new standard of mental healthcare. For more information visit

Contact Information

Yaron Conforti, CEO
T: +1 (647) 953 9512